Ozempic diabetes competitor gets PBS knockback

Eli Lilly’s Mounjaro would need “substantial price reduction”, says PBAC Mounjaro, the type-2 diabetes medication that the New York Times recently predicted “’could overshadow Ozempic” has been refused funding via the Pharmaceutical Benefits Scheme (PBS). In the latest outcomes from the Pharmaceutical Benefits Advisory Committee’s July meeting, the body said it “did not recommend tirzepatide